Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Cardiol Therapeutics Presented Topline Data From Its Phase II MAvERIC-Pilot Study Investigating CardiolRx For Recurrent Pericarditis; Administration Of CardiolRx Led To A Marked Reduction In The Primary Efficacy Endpoint Of Pericarditis Pain
Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ("TP"), as well as normalization of inflammation - as measured by C-reactive protein ("CRP") - in 80% of patients with elevated CRP at baseline.Administration of CardiolRx led to a marked reduction in the primary efficacy endpoint of pericarditis pain
CardiolRx治疗导致渗出性心包炎疼痛的主要疗效终点明显降低。
CardiolRx also shown to reduce inflammation in patients with elevated CRP
CardiolRx还显示可减少CRP升高患者的炎症。
89% of patients have continued into the extension phase of the study
89%的病人已进入研究的延长期。
Toronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis. The data showed a substantial reduction in the primary efficacy endpoint of patient-reported pericarditis pain at the end of the 8-week treatment period ("TP"), as well as normalization of inflammation - as measured by C-reactive protein ("CRP") - in 80% of patients with elevated CRP at baseline.
加拿大安大略省--(Newsfile corp. - 2024年6月13日) - Cardiol Therapeutics公司（纳斯达克股票代码：CRDL，tsx股票代码：CRDL）（以下简称：“卡迪尔”或“公司”），一家专注于研究和临床开发心脏病抗炎和抗纤维化疗法的临床阶段生命科学公司，今天公布了开放标签MAvERIC-Pilot研究的8周临床数据，该研究调查了CardiolRx对具有症状性反复性心包炎的患者的影响。数据显示，在8周的治疗期（“TP”）结束时，患者报告的心包炎疼痛主要疗效终点有显著减少，并且80%的患者的C-反应蛋白（“CRP”）水平在治疗前有所提高，治疗后正常化。
